Acknowledging the amplified advantages of combining SGLT2 inhibitors and selective MRAs in mitigating CKD progression, particularly in patients on renin–angiotensin–aldosterone system (RAAS) inhibitors, we conducted a retrospective analysis utilizing real-world data to evaluate their effectiveness in reducing albuminuria, a key marker of CKD progression, and its impact on the risk of hyperkalemia. The gene discussed is SLC5A2; the disease is Hyperkalemia.